\begin{table}[htbp]
\centering
\caption{Singapore Cohort Demographics and Clinical Characteristics (N=42)}
\label{tab:ch18-demographics}
\small
\begin{tabular}{lcc}
\toprule
\textbf{Characteristic} & \textbf{N (\%)} & \textbf{Notes} \\
\midrule
\textbf{Age at enrollment} & & \\
\quad Median (range) & 54 years (32--72) & \\
\quad $<$ 50 years & 15 (35.7\%) & Premenopausal enriched \\
\quad 50--64 years & 19 (45.2\%) & Peri/postmenopausal \\
\quad $\ge$ 65 years & 8 (19.0\%) & Elderly \\[6pt]

\textbf{Ethnicity} & & \\
\quad Chinese & 31 (73.8\%) & Dominant in Singapore \\
\quad Malay & 7 (16.7\%) & \\
\quad Indian & 4 (9.5\%) & \\[6pt]

\textbf{ER/PR status} & & \\
\quad ER+/PR+ & 34 (81.0\%) & Standard Tamoxifen indication \\
\quad ER+/PR- & 8 (19.0\%) & \\[6pt]

\textbf{Tamoxifen duration} & & \\
\quad $<$ 2 years & 5 (11.9\%) & Early discontinuation \\
\quad 2--5 years & 22 (52.4\%) & Standard course \\
\quad $>$ 5 years & 15 (35.7\%) & Extended therapy \\[6pt]

\textbf{Concomitant CYP2D6 inhibitors} & 11 (26.2\%) & SSRIs, SNRIs, others \\[6pt]

\textbf{Follow-up outcomes} & & \\
\quad Disease-free survival & 36 (85.7\%) & Median 4.2 years \\
\quad Recurrence & 4 (9.5\%) & All Intermediate/Poor phenotype \\
\quad Lost to follow-up & 2 (4.8\%) & \\
\bottomrule
\end{tabular}
\end{table}